Today's Veterinary Practice

JUL-AUG 2014

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: http://todaysveterinarypractice.epubxp.com/i/354788

Contents of this Issue

Navigation

Page 23 of 83

| KeraToconjuncTiviTis sicca in Dogs Today's veterinary Practice July/August 2014 22 tvpjournal.com phenazopyridine in dogs. Arch Ophthalmol 1973; 90(4):310-311. 15. Saito A, Izumisawa Y, Yamashita K, Kotani T. The effect of third eyelid gland removal on the ocular surface of dogs. Vet Ophthalmol 2001; 4(1):13-18. 16. Spugnini EP, Thrall DE, Price S, et al. Primary irradiation of canine intracranial masses. Vet Radiol Ultrasound 2000; 41(4):377-380. 17. Sansom J, Barnett KC. Keratoconjunctivitis sicca in the dog: A review of two hundred cases. J Small Anim Pract 1985; 26(3):121-131. 18. Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract 1990; 20(3):583-613. 19. Moore CP. Qualitative tear film disease. Vet Clin North Am Sm Anim Pract 1990; 20(3):565-581. 20. Moore CP, Collier LL. Ocular surface disease associated with the loss of conjunctival goblet cells in dogs. JAAHA 1990; 26(5):458-465. 21. Hess AD. Mechanisms of action of cyclosporine: Considerations for treatment of autoimmune diseases. Clin Immunol Immunopathol 1993; 68(2):220-228. 22. Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci 2001; 42(3):653-659. 23. Palmer SL, Bowen PA, Green K. Tear flow in cyclosporine recipients. Ophthalmol 1995; 102(1):118-121. 24. Olivero DK, Davidson MG, English RV, et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. JAVMA 1991; 199(8):1039-1042. 25. Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. JAVMA 1991; 199(8):1043- 1046. 26. Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 2005; 8(4):225-232. 27. Hendrix DVH, Adkins EA, Ward DA, et al. An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs. Vet Med Inter 2011; 2011:487592. 28. Smith EM, Buyukmihci NC, Faryer TB. Effect of topical pilocarpine treatment on tear production in dogs. JAVMA 1994; 205(9):1286-1289. 29. Rhodes M, Heinrich C, Featherstone H, et al. Parotid duct transposition in dogs: A retrospective review of 92 eyes from 1999-2009. Vet Ophthalmol 2012; 15(4):213-222. 30. Dreyfus J, Schobert CS, Dubielzig RR. Superficial corneal squamous cell carcinoma occurring in dogs with chronic keratitis. Vet Ophthalmol 2011; 14(13):161-168. Lori J. Best, DVM, is a first-year oph- thalmology resident at University of Ten- nessee College of Veterinary Medicine. She received her DVM from Colorado State University and completed her small animal rotating internship at University of Tennessee. Diane V.H. Hendrix, DVM, Diplomate ACVO, is a professor of ophthalmology at University of Tennessee College of Vet- erinary Medicine. She received the Zoetis Distinguished Veterinary Teaching Award in 2013. Dr. Hendrix received her DVM from University of Tennessee and com- pleted her residency in comparative ophthalmology at Uni- versity of Florida. Dan A. Ward, DVM, PhD, Diplomate ACVO, is a professor of ophthalmology at University of Tennessee College of Vet- erinary Medicine. He received the Pfizer Distinguished Professor Award in 2012. Dr. Ward received his DVM from Uni- versity of Tennessee and completed his ophthalmology residency, PhD in phar- macology, and postdoctoral work in clinical pharmacology at University of Georgia. VETROPOLYCIN ® (bacitracin-neomycin-polymyxin) Veterinary Ophthalmic Ointment NADA # 065-016. Approved by FDA. WARNING: Do not use this product as a pre-surgical ocular lubricant. Adverse reactions of ocular irritation and corneal ulceration have been reported in association with such use. VETROPOLYCIN ® HC (bacitracin-neomycin-polymyxin- hydrocortisone acetate 1%) Veterinary Ophthalmic Ointment NADA # 065-015. Approved by FDA. CONTRAINDICATIONS: Ophthalmic preparations containing corticosteroids are contraindicated in the treatment of those deep, ulcerative lesions of the cornea where the inner layer (endothelium) is involved, in fungal infections and in the presence of viral infections. WARNINGS: All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent, are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well under way. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the frst stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. THE INfORmATION bELOW APPLIES TO bOTH VETROPOLYCIN AND VETROPOLYCIN HC. STERILE - ANTIbACTERIAL CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. PRECAUTIONS: Sensitivity to these ophthalmic ointments is rare, however, if a reaction occurs, discontinue use of the preparation. The prolonged use of antibiotic-containing preparations may result in overgrowth of nonsusceptible organisms including fungi. Appropriate measures should be taken if this occurs. If infection does not respond to treatment in two or three days, the diagnosis and therapy should be reevaluated. Animals under treatment with VETROPOLYCIN HC (bacitracin-neomycin- polymyxin with hydrocortisone acetate 1 %) should be observed for usual signs of corticosteroid overdose which include polydipsia, polyuria and occasionally an increase in weight. Use of corticosteroids, depending on dose, duration, and specifc steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations. Care should be taken not to contaminate the applicator tip during administration of the preparation. ADVERSE REACTIONS: Itching, burning or infammation may occur in animals sensitive to the product. Discontinue use in such cases. SAP and SGPT (ALT) enzyme elevations, polydypsia and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy. Manufactured for: Dechra Veterinary Products 7015 College Boulevard, Suite 525 Overland Park, KS 66211 866-933-2472

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - JUL-AUG 2014